

## CLAIM AMENDMENTS

1.-79. (cancelled)

80. (previously presented) An isolated ELR-CXC chemokine antagonist, consisting of the amino acid sequence set forth in SEQ ID NO:1.

81. (currently amended) An isolated ELR-CXC chemokine antagonist having comprising the amino acid sequence as set forth in SEQ ID No. 1 but wherein amino acid 30 of SEQ ID NO:1 is Gly instead of Pro and amino acid 29 of SEQ ID NO: 1 is glycine instead of proline.

82. (currently amended) An isolated ELR-CXC chemokine antagonist having comprising the amino acid sequence as set forth in SEQ ID No. 1 but wherein amino acid 10 of SEQ ID NO:1 is Ser instead of Thr and amino acid 11 of SEQ ID NO: 1 is Phe instead of His.

83. (currently amended) An isolated ELR-CXC chemokine antagonist having comprising the amino acid sequence as set forth in SEQ ID No. 1 but wherein amino acid 11 of SEQ ID NO:1 is Phe instead of His, amino acid 10 of SEQ ID NO:1 is Ser instead of Thr, amino acid 30 of SEQ ID NO:1 is Gly instead of Pro and amino acid 29 of SEQ ID NO:1 is glycine instead of proline.

84. (previously presented) A method for treating an ELR-CXC chemokine-mediated pathology, said pathology selected from the group consisting of ischemia-reperfusion injury, acute respiratory distress syndrome, immune complex-type glomerulonephritis, bacterial pneumonia and mastitis, in which an ELR-CXC chemokine binds to CXCR1 or CXCR2 receptors in a mammal, the method comprising administering to said mammal an effective amount of the ELR-CXC chemokine antagonist as recited in claim 80.

85. cancelled

86. (previously presented) The method of claim 84, wherein the pathology is acute respiratory distress syndrome.